Equities Analysts Set Expectations for XENE FY2025 Earnings

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) – Research analysts at William Blair upped their FY2025 earnings per share (EPS) estimates for Xenon Pharmaceuticals in a report issued on Tuesday, November 4th. William Blair analyst M. Minter now anticipates that the biopharmaceutical company will post earnings of ($4.26) per share for the year, up from their prior forecast of ($4.32). William Blair has a “Outperform” rating on the stock. The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($3.10) per share. William Blair also issued estimates for Xenon Pharmaceuticals’ Q4 2025 earnings at ($1.21) EPS, Q1 2026 earnings at ($0.95) EPS, Q2 2026 earnings at ($1.15) EPS, Q3 2026 earnings at ($1.19) EPS, Q4 2026 earnings at ($1.25) EPS, FY2026 earnings at ($4.53) EPS and FY2027 earnings at ($5.48) EPS.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its earnings results on Monday, November 3rd. The biopharmaceutical company reported ($1.15) EPS for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.01. During the same period in the previous year, the company posted ($0.81) earnings per share. Xenon Pharmaceuticals’s revenue was up .0% compared to the same quarter last year.

Several other analysts also recently issued reports on XENE. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research note on Tuesday, October 14th. Wedbush upped their price target on Xenon Pharmaceuticals from $42.00 to $43.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 12th. Royal Bank Of Canada upped their price target on Xenon Pharmaceuticals from $55.00 to $58.00 and gave the stock an “outperform” rating in a research note on Tuesday. Bloom Burton upgraded Xenon Pharmaceuticals to a “strong-buy” rating in a research note on Tuesday, October 7th. Finally, Wells Fargo & Company reiterated an “overweight” rating and set a $44.00 price target (down previously from $48.00) on shares of Xenon Pharmaceuticals in a research note on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $53.70.

Xenon Pharmaceuticals Price Performance

Shares of NASDAQ XENE opened at $38.66 on Thursday. The business’s 50-day moving average price is $39.40 and its two-hundred day moving average price is $35.43. Xenon Pharmaceuticals has a one year low of $26.74 and a one year high of $46.00. The company has a market capitalization of $2.98 billion, a P/E ratio of -10.89 and a beta of 1.10.

Insider Activity

In other news, CEO Ian Mortimer sold 25,000 shares of the stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $40.16, for a total value of $1,004,000.00. Following the completion of the transaction, the chief executive officer directly owned 31,302 shares of the company’s stock, valued at approximately $1,257,088.32. This represents a 44.40% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 4.07% of the company’s stock.

Institutional Investors Weigh In On Xenon Pharmaceuticals

A number of large investors have recently bought and sold shares of XENE. Farther Finance Advisors LLC bought a new position in Xenon Pharmaceuticals in the 2nd quarter valued at $25,000. Caitong International Asset Management Co. Ltd bought a new position in Xenon Pharmaceuticals in the 1st quarter valued at $30,000. Elevation Point Wealth Partners LLC bought a new position in Xenon Pharmaceuticals in the 2nd quarter valued at $32,000. State of Wyoming boosted its position in Xenon Pharmaceuticals by 112.8% in the 3rd quarter. State of Wyoming now owns 1,151 shares of the biopharmaceutical company’s stock valued at $46,000 after buying an additional 610 shares during the last quarter. Finally, Osaic Holdings Inc. boosted its position in Xenon Pharmaceuticals by 541.4% in the 2nd quarter. Osaic Holdings Inc. now owns 1,225 shares of the biopharmaceutical company’s stock valued at $40,000 after buying an additional 1,034 shares during the last quarter. 95.45% of the stock is currently owned by institutional investors.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.